These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7747009)

  • 1. [Open therapeutic trial of anti-T CD4 monoclonal antibody in multiple sclerosis].
    Rumbach L; Racadot E; Bataillard M; Galmiche J; Henlin JL; Trutmann M; Ziegler F; Wijdenes J
    Rev Neurol (Paris); 1994; 150(6-7):418-24. PubMed ID: 7747009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients.
    Rumbach L; Racadot E; Armspach JP; Namer IJ; Bonneville JF; Wijdenes J; Marescaux C; Herve P; Chambron J
    Mult Scler; 1996 Feb; 1(4):207-12. PubMed ID: 9345436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients.
    Racadot E; Rumbach L; Bataillard M; Galmiche J; Henlin JL; Truttmann M; Herve P; Wijdenes J
    J Autoimmun; 1993 Dec; 6(6):771-86. PubMed ID: 8155256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
    Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
    J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
    Lindsey JW; Hodgkinson S; Mehta R; Mitchell D; Enzmann D; Steinman L
    Ann Neurol; 1994 Aug; 36(2):183-9. PubMed ID: 8053654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects.
    Lorenz HM; Antoni C; Valerius T; Repp R; Grünke M; Schwerdtner N; Nüsslein H; Woody J; Kalden JR; Manger B
    J Immunol; 1996 Feb; 156(4):1646-53. PubMed ID: 8568271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
    Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
    J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
    Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
    Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interleukin 10 in disseminated lupus erythematosus].
    Emilie D
    J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
    Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
    Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1.
    Watabe D; Kanno H; Yoshida A; Kurose A; Akasaka T; Sawai T
    Br J Dermatol; 2007 Aug; 157(2):259-65. PubMed ID: 17596165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
    van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
    J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis.
    Garfield BE; Krahl T; Appel S; Cooper SM; Rincón M
    Clin Immunol; 2005 Aug; 116(2):101-7. PubMed ID: 15914087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
    Aeberli D; Seitz M; Jüni P; Villiger PM
    Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of CD4(+)CD28null T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina.
    Rizzello V; Liuzzo G; Brugaletta S; Rebuzzi A; Biasucci LM; Crea F
    Circulation; 2006 May; 113(19):2272-7. PubMed ID: 16682617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
    Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
    Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.